Needham analyst Ami Fadia initiates coverage on Praxis Precision Medicine (NASDAQ:PRAX) with a Buy rating and announces Price Target of $145.
Needham Initiates Coverage On Praxis Precision Medicine With Buy Rating, Announces Price Target of $145
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.